
Zeruesenay Desta, PhD
Professor of Medicine
Bio
The goal of effective and safe therapy of many drugs is made difficult by large interindividual variability in response to these drugs and is of major concern for patients, and their caretakers and significantly adversely influences the cost of health care. Our ultimate goals are comprehensive understanding of mechanisms controlling interindividual variability in drug response and then apply this knowledgebase to maximize beneficial and minimize adverse effects of medications for the individual patient. Although potential causes for variable drug effects are multiple, interpatient differences in drug disposition and unpredictable drug-drug interactions (DDIs) are frequent and major determinants of beneficial and adverse drug effects. Thus, our research focuses on identifying factors that contribute to variable drug disposition. Completed and ongoing bench and clinical studies in our laboratory address the impact of altered drug metabolizing enzymes and drug transporters due to genetic polymorphisms and nongenetic factors (e.g., DDIs) on exposure of drugs and (active) metabolites. Our research activities include: developing new analytical tools to measure drugs and their metabolites; profiling of drug metabolites; identification of rate limiting metabolic pathways and the specific enzymes involved; developing and validating novel molecular and clinical tools to study drug disposition and DDIs; assessing the impact of genetic variants and DDIs as well as interplay of them on drug exposure and effect; and developing mathematical models (e.g. static models, PBPK and popPK) to allow mechanistic understanding and quantitative prediction of clinical drug exposure and DDIs from in vitro data. Basic discoveries are made using in vitro model systems. Then, complementary clinical studies are designed in healthy volunteers at the Indiana Clinical Research Center or in patients to verify clinical significance. Dr. Desta has >20 years of experience and extensive publication record (> 130 peer-reviewed) in this area of this research. Our laboratory has made seminal discoveries including new active metabolites (e.g., endoxifen), multiple in vitro and in vivo biochemical, clinical and genetic approaches to study CYPs, and clinical studies that lead to changes in FDA drug labelling (e.g., tamoxifen, pimozide, and efavirenz). We have continuously competed and received funding from the NIH as a PI or Co-I to pursue collaborative research.
Titles & Appointments
- Professor of Medicine
- Adjunct Professor of Pharmacology & Toxicology
- Associate Division Chief, Clinical Pharmacology
- Scientific Director, Clinical Pharmacology Analytical Core
- Director, Clinical Pharmacology Training Program
-
Education1990 PhD Ernst Moritz Arndt University1988 MSC Martin Luther University1982 BPHARM Addis Ababa University
-
PublicationsRisk factors for early language delay in children within a minority ethnic, bilingual, deprived environment (Born in Bradford's Better Start): a UK community birth cohort study.
Cheung RW; Willan K; Dickerson J; Bowyer-Crane C; BMJ paediatrics open 2023 MarInfluence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.
Gufford BT; Metzger IF; Bamfo NO; Benson EA; Masters AR; Lu JBL; Desta Z; The Journal of pharmacology and experimental therapeutics 2022 Jul 7Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers.
Shugg T; Ly RC; Rowe EJ; Philips S; Hyder MA; Radovich M; Rosenman MB; Pratt VM; Callaghan JT; Desta Z; Schneider BP; Skaar TC; JCO precision oncology 2022 FebPharmVar GeneFocus: CYP2B6.
Desta Z; El-Boraie A; Gong L; Somogyi AA; Lauschke VM; Dandara C; Klein K; Miller NA; Klein TE; Tyndale RF; Whirl-Carrillo M; Gaedigk A; Clinical pharmacology and therapeutics 2021 Mar 11Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program.
Titus-Lay EN; Jaynes HA; Tomaselli Muensterman E; Walroth TA; Ott CA; Desta Z; Williams G; Moe PR; Wilbrandt M; Tisdale JE; Pharmacotherapy 2021 Feb 2Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ; Thomas CD; Barbarino J; Desta Z; Van Driest SL; El Rouby N; Johnson JA; Cavallari LH; Shakhnovich V; Thacker DL; Scott SA; Schwab M; Uppugunduri CRS; Formea CM; Franciosi JP; Sangkuhl K; Gaedigk A; Klein TE; Gammal RS; Furuta T; Clinical pharmacology and therapeutics 2020 Sep 20Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity.
Ipe J; Li R; Metzger IF; Bo Li Lu J; Gufford BT; Desta Z; Liu Y; Skaar TC; Clinical pharmacology and therapeutics 2020 Oct 5Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor a.
Ingle JN; Cairns J; Suman VJ; Shepherd LE; Fasching PA; Hoskin TL; Singh RJ; Desta Z; Kalari KR; Ellis MJ; Goss PE; Chen BE; Volz B; Barman P; Carlson EE; Haddad TC; Goetz MP; Goodnature B; Cuellar ME; Walters MA; Correia C; Kaufmann SH; Weinshilboum RM; Wang L; Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Feb 25Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Gufford BT; Lu JBL; Bushman LR; Anderson PL; Bergstrom RF; Desta Z; Gupta SK; Clinical pharmacology and therapeutics 2019 Nov 1Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Dudenkov TM; Liu D; Cairns J; Devarajan S; Zhuang Y; Ingle JN; Buzdar AU; Robson ME; Kubo M; Batzler A; Barman P; Jenkins GD; Carlson EE; Goetz MP; Northfelt DW; Moreno-Aspitia A; Desta Z; Reid JM; Kalari KR; Wang L; Weinshilboum RM; Clinical pharmacology and therapeutics 2019 Mar 18Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL; Pharmacogenomics 2019 JunClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
Desta Z; Gammal RS; Gong L; Whirl-Carrillo M; Gaur AH; Sukasem C; Hockings J; Myers A; Swart M; Tyndale RF; Masimirembwa C; Iwuchukwu OF; Chirwa S; Lennox J; Gaedigk A; Klein TE; Haas DW; Clinical pharmacology and therapeutics 2019 Jul 5Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.
Liu SN; Lu JBL; Watson CJW; Lazarus P; Desta Z; Gufford BT; Drug metabolism and disposition: the biological fate of chemicals 2019 Feb 25Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.
Fulton CR; Zang Y; Desta Z; Rosenman MB; Holmes AM; Decker BS; Zhang Y; T Callaghan J; Pratt VM; Levy KD; Gufford BT; Dexter PR; Skaar TC; Eadon MT; Pharmacogenomics 2019 Feb 20Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2019 Dec 30Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Desta Z; Gufford BT; CPT: pharmacometrics & systems pharmacology 2019 Dec 23Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics.
Wu HY; Shendre A; Zhang S; Zhang P; Wang L; Zeruesenay D; Rocha LM; Shatkay H; Quinney SK; Ning X; Li L; Clinical pharmacology and therapeutics 2019 Dec 21CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z; Clinical and translational science 2019 Aug 12DrugMetab: An Integrated Machine Learning and Lexicon Mapping Named Entity Recognition Method for Drug Metabolite.
Wu HY; Lu D; Hyder M; Zhang S; Quinney SK; Desta Z; Li L; CPT: pharmacometrics & systems pharmacology 2018 Sep 29Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.
Fulton CR; Swart M; De Luca T; Liu SN; Collins KS; Desta Z; Gufford BT; Eadon MT; The journal for nurse practitioners : JNP 2018 Nov 2Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes.
Gufford BT; Robarge JD; Eadon MT; Gao H; Lin H; Liu Y; Desta Z; Skaar TC; Pharmacology research & perspectives 2018 Mar 26CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
Skaar TC; Desta Z; Clinical pharmacology and therapeutics 2018 Feb 23Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.
Burgess KS; Ipe J; Swart M; Metzger IF; Lu J; Gufford BT; Thong N; Desta Z; Gaedigk R; Pearce RE; Gaedigk A; Liu Y; Skaar TC; Clinical pharmacology and therapeutics 2017 Sep 27Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Marcath LA; Deal AM; Van Wieren E; Danko W; Walko CM; Ibrahim JG; Weck KE; Jones DR; Desta Z; McLeod HL; Carey LA; Irvin WJ Jr; Hertz DL; Pharmacogenetics and genomics 2017 NovClinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial.
Pierson RC; Gufford BT; Desta Z; Eadon MT; Pharmacogenomics 2017 Jun 8Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Hertz DL; Speth KA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Breast cancer research and treatment 2017 Jun 22Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z; Metzger IF; Thong N; Lu JB; Callaghan JT; Skaar TC; Flockhart DA; Galinsky RE; Antimicrobial agents and chemotherapy 2016 Oct 21Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ Jr; The oncologist 2016 May 25Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL; The oncologist 2016 Mar 23Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.
Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z; The Journal of pharmacology and experimental therapeutics 2016 Jun 2Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR; Journal of cardiovascular electrophysiology 2016 Jul 25Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.
Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2016 Jan 22Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
Eadon MT; Desta Z; Levy KD; Decker BS; Pierson RC; Pratt VM; Callaghan JT; Rosenman MB; Carpenter JS; Holmes AM; McDonald CA; Benson EA; Patil AS; Vuppalanchi R; Gufford BT; Dave N; Robarge JD; Hyder MA; Haas DM; Kreutz RP; Dexter PR; Skaar TC; Flockhart DA; Clinical pharmacology and therapeutics 2016 Feb 6Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.
Masters AR; McCoy M; Jones DR; Desta Z; Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2016 Feb 18Obituary: David Alastair Flockhart , MD, PhD.
Bies R; McDonald C; Desta Z; British journal of clinical pharmacology 2016 FebEffects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL; Breast cancer research and treatment 2016 Dec 9Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
Robarge JD; Metzger IF; Lu J; Thong N; Skaar TC; Desta Z; Bies RR; Antimicrobial agents and chemotherapy 2016 Dec 27Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
Hertz DL; Kidwell KM; Seewald NJ; Gersch CL; Desta Z; Flockhart DA; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; The pharmacogenomics journal 2016 Aug 23Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.
Benson EA; Eadon MT; Desta Z; Liu Y; Lin H; Burgess KS; Segar MW; Gaedigk A; Skaar TC; Frontiers in pharmacology 2016 Apr 26Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.
Han X; Quinney SK; Wang Z; Zhang P; Duke J; Desta Z; Elmendorf JS; Flockhart DA; Li L; Clinical pharmacology and therapeutics 2015 SepAssociation of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA); Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Oct 13Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA; Breast cancer research and treatment 2015 Nov 4A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.
Eadon MT; Zhang H; Skaar TC; Hato T; Dagher PC; Gupta SK; Desta Z; Antiviral chemistry & chemotherapy 2015 Jul 30Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z; Drug metabolism and pharmacokinetics 2015 Jul 29In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-Glucuronosyltransferases.
Cardoso Jde O; Oliveira RV; Lu JB; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2015 DecIn vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ Jr; British journal of clinical pharmacology 2015 Aug 2Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver.
Burgess KS; Philips S; Benson EA; Desta Z; Gaedigk A; Gaedigk R; Segar MW; Liu Y; Skaar TC; Clinical pharmacology and therapeutics 2015 AugSubstantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
Metzger IF; Quigg TC; Epstein N; Aregbe AO; Thong N; Callaghan JT; Flockhart DA; Nguyen AT; Stevens CK; Gupta SK; Desta Z; Current therapeutic research, clinical and experimental 2014 Sep 27Genome-wide discovery of drug-dependent human liver regulatory elements.
Smith RP; Eckalbar WL; Morrissey KM; Luizon MR; Hoffmann TJ; Sun X; Jones SL; Force Aldred S; Ramamoorthy A; Desta Z; Liu Y; Skaar TC; Trinklein ND; Giacomini KM; Ahituv N; PLoS genetics 2014 Oct 2Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Kreutz RP; Bitar A; Owens J; Desta Z; Breall JA; von der Lohe E; Sinha A; Vatta M; Nystrom P; Jin Y; Flockhart DA; Journal of thrombosis and thrombolysis 2014 OctPrerequisites to implementing a pharmacogenomics program in a large health-care system.
Levy KD; Decker BS; Carpenter JS; Flockhart DA; Dexter PR; Desta Z; Skaar TC; Clinical pharmacology and therapeutics 2014 May 7Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Kreutz RP; Owens J; Lu D; Nystrom P; Jin Y; Kreutz Y; Desta Z; Flockhart DA; Platelets 2014 May 15PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
Lowenberg D; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE; Pharmacogenetics and genomics 2014 FebEstrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM; Steroids 2014 Aug 24Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM; British journal of clinical pharmacology 2014 AugAromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Henry NL; Chan HP; Dantzer J; Goswami CP; Li L; Skaar TC; Rae JM; Desta Z; Khouri N; Pinsky R; Oesterreich S; Zhou C; Hadjiiski L; Philips S; Robarge J; Nguyen AT; Storniolo AM; Flockhart DA; Hayes DF; Helvie MA; Stearns V; British journal of cancer 2013 Oct 1Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
Abdelhady AM; Desta Z; Jiang F; Yeo CW; Shin JG; Overholser BR; Journal of clinical pharmacology 2013 Nov 19PharmGKB summary: tamoxifen pathway, pharmacokinetics.
Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE; Pharmacogenetics and genomics 2013 NovGenome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.
Weng L; Ziliak D; Im HK; Gamazon ER; Philips S; Nguyen AT; Desta Z; Skaar TC; Consortium on Breast Cancer Pharmacogenomics (COBRA); Flockhart DA; Huang RS; Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Mar 18CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.
Xu C; Quinney SK; Guo Y; Hall SD; Li L; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2013 Jul 11Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
Jiang F; Desta Z; Shon JH; Yeo CW; Kim HS; Liu KH; Bae SK; Lee SS; Flockhart DA; Shin JG; British journal of clinical pharmacology 2013 JanIn vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.
Xu C; Desta Z; Drug metabolism and pharmacokinetics 2013 Feb 5CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.
Love RR; Desta Z; Flockhart D; Skaar T; Ogburn ET; Ramamoorthy A; Uy GB; Laudico AV; Van Dinh N; Quang le H; Van To T; Young GS; Hade E; Jarjoura D; SpringerPlus 2013 Feb 15Cytochrome P450 3A4*22, PPAR-a, and ARNT polymorphisms and clopidogrel response.
Kreutz RP; Owens J; Jin Y; Nystrom P; Desta Z; Kreutz Y; Breall JA; Li L; Chiang C; Kovacs RJ; Flockhart DA; Clinical pharmacology : advances and applications 2013 Dec 9Regulation of microRNA expression by rifampin in human hepatocytes.
Ramamoorthy A; Liu Y; Philips S; Desta Z; Lin H; Goswami C; Gaedigk A; Li L; Flockhart DA; Skaar TC; Drug metabolism and disposition: the biological fate of chemicals 2013 Aug 9Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial.
Gupta SK; Mi D; Dubé MP; Saha CK; Johnson RM; Stein JH; Clauss MA; Mather KJ; Desta Z; Liu Z; PloS one 2013 Apr 9Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.
Michaud V; Kreutz Y; Skaar T; Ogburn E; Thong N; Flockhart DA; Desta Z; The pharmacogenomics journal 2013 Apr 30Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL; Skaar TC; Dantzer J; Li L; Kidwell K; Gersch C; Nguyen AT; Rae JM; Desta Z; Oesterreich S; Philips S; Carpenter JS; Storniolo AM; Stearns V; Hayes DF; Flockhart DA; Breast cancer research and treatment 2013 Apr 2Histoplasma capsulatum preferentially induces IDO in the lung.
Hage CA; Horan DJ; Durkin M; Connolly P; Desta Z; Skaar TC; Knox KS; Wheat LJ; Medical mycology 2012 Nov 27Stereoselective and regiospecific hydroxylation of ketamine and norketamine.
Desta Z; Moaddel R; Ogburn ET; Xu C; Ramamoorthy A; Venkata SL; Sanghvi M; Goldberg ME; Torjman MC; Wainer IW; Xenobiotica; the fate of foreign compounds in biological systems 2012 May 21Compartment-specific gene regulation of the CAR inducer efavirenz in vivo.
Meyer zu Schwabedissen HE; Oswald S; Bresser C; Nassif A; Modess C; Desta Z; Ogburn ET; Marinova M; Lütjohann D; Spielhagen C; Nauck M; Kroemer HK; Siegmund W; Clinical pharmacology and therapeutics 2012 May 16Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y; Platelets 2012 Mar 2The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA; Pharmacological reviews 2012 JulEffects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2012 Jan 9Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Michaud V; Ogburn E; Thong N; Aregbe AO; Quigg TC; Flockhart DA; Desta Z; Clinical pharmacology and therapeutics 2012 Feb 8Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Desta Z; Breall JA; Li L; Chiang C; Kovacs R; Flockhart DA; Jin Y; Clinical pharmacology : advances and applications 2012 Feb 20Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Henry NL; Azzouz F; Desta Z; Li L; Nguyen AT; Lemler S; Hayden J; Tarpinian K; Yakim E; Flockhart DA; Stearns V; Hayes DF; Storniolo AM; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Feb 13Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
Oswald S; Meyer zu Schwabedissen HE; Nassif A; Modess C; Desta Z; Ogburn ET; Mostertz J; Keiser M; Jia J; Hubeny A; Ulrich A; Runge D; Marinova M; Lütjohann D; Kroemer HK; Siegmund W; Clinical pharmacology and therapeutics 2012 Feb 1Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
Thacker DL; Modak A; Flockhart DA; Desta Z; Journal of breath research 2012 Dec 21Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
Ji Y; Biernacka JM; Hebbring S; Chai Y; Jenkins GD; Batzler A; Snyder KA; Drews MS; Desta Z; Flockhart D; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Schaid D; Weinshilboum RM; Mrazek DA; The pharmacogenomics journal 2012 Aug 21Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
Thacker DL; Modak A; Nguyen PD; Flockhart DA; Desta Z; Chirality 2011 Sep 20Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Desta Z; Kreutz Y; Nguyen AT; Li L; Skaar T; Kamdem LK; Henry NL; Hayes DF; Storniolo AM; Stearns V; Hoffmann E; Tyndale RF; Flockhart DA; Clinical pharmacology and therapeutics 2011 Oct 5Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Lu WJ; Desta Z; Flockhart DA; Breast cancer research and treatment 2011 Mar 9Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Irvin WJ Jr; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jul 18Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.
Cho DY; Ogburn ET; Jones D; Desta Z; Antimicrobial agents and chemotherapy 2011 Jan 31Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN; Nguyen AT; Li L; Desta Z; Henry NL; Hayes DF; Wolff AC; Stearns V; Storniolo AM; Flockhart DA; Consortium on Breast Cancer Pharmacogenomics (COBRA); Journal of clinical pharmacology 2011 Dec 15Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
Montenegro MF; Ceron CS; Salgado MC; Desta Z; Flockhart DA; Tanus-Santos JE; Journal of cardiovascular pharmacology 2011 DecAbacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M; Antiviral therapy 2011In vitro cytochrome P450-mediated metabolism of exemestane.
Kamdem LK; Flockhart DA; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2010 Sep 28In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Kamdem LK; Liu Y; Stearns V; Kadlubar SA; Ramirez J; Jeter S; Shahverdi K; Ward BA; Ogburn E; Ratain MJ; Flockhart DA; Desta Z; British journal of clinical pharmacology 2010 Dec